[{"indications": "Indications\u00a0\n(From 6.1.2.3 Other antidiabetic drugs: British National Formulary)\n6.1.2.3 Other antidiabetic drugs", "name": "SITAGLIPTIN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.1 Drugs used in diabetes", "6.1.2 Antidiabetic drugs", "6.1.2.3 Other antidiabetic drugs"], "cautions": "Cautions\u00a0discontinue if symptoms of acute pancreatitis\r\n(persistent, severe abdominal pain); interactions: Appendix 1 (antidiabetics)", "side-effects": "Side-effects\u00a0gastro-intestinal disturbances; peripheral oedema;\r\nupper respiratory tract infection, nasopharyngitis; pain; less commonly dry mouth, anorexia, headache, drowsiness,\r\ndizziness, hypoglycaemia, osteoarthritis; also reported pancreatitis, rash, cutaneous vasculitis, and Stevens-Johnson syndrome", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/130071.htm", "doses": ["adult over 18 years, 100\u00a0mg\r\nonce daily", "Dose of concomitant sulfonylurea\r\nor insulin may need to be reduced"], "pregnancy": "Pregnancy\u00a0avoid\u2014toxicity in animal studies"}, {"indications": "Indications\u00a0type 2 diabetes mellitus not controlled\r\nby metformin alone or by metformin in combination\r\nwith either a sulfonylurea or pioglitazone or insulin", "name": "SITAGLIPTIN WITH METFORMIN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.1 Drugs used in diabetes", "6.1.2 Antidiabetic drugs", "6.1.2.3 Other antidiabetic drugs"], "cautions": "Cautions\u00a0determine renal function before treatment\r\nand at least annually (at least twice a year in patients with additional\r\nrisk factors for renal impairment, or if deterioration suspected); discontinue if symptoms of acute pancreatitis (persistent,\r\nsevere abdominal pain); interactions: Appendix 1 (antidiabetics)Lactic acidosis\u00a0Use with caution in renal impairment\u2014increased risk of lactic acidosis; avoid if eGFR less than 50\u00a0mL/minute/1.73\u00a0m2. Withdraw or interrupt treatment in those at risk of\r\ntissue hypoxia or sudden deterioration in renal function, such as\r\nthose with dehydration, severe infection, shock, sepsis, acute heart\r\nfailure, respiratory failure or hepatic impairment, or those who have\r\nrecently had a myocardial infarction", "side-effects": "Side-effects\u00a0gastro-intestinal disturbances (including nausea,\r\nvomiting, abdominal pain, flatulence, diarrhoea (usually transient),\r\nconstipation), taste disturbance, anorexia; peripheral oedema, upper\r\nrespiratory tract infection, nasopharyngitis; pain; less commonly dry mouth, headache, drowsiness, dizziness, hypoglycaemia, osteoarthritis; very rarely lactic acidosis (withdraw treatment), decreased\r\nvitamin-B12 absorption, erythema, pruritus, and urticaria; also reported pancreatitis, hepatitis, rash, cutaneous vasculitis,\r\nand Stevens-Johnson syndrome ", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/207519.htm", "doses": ["See under preparation"], "pregnancy": "Pregnancy\u00a0avoid\u2014toxicity in animal studies"}]